Obesity pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
ClassNone selected
MechanismNone selected
Phase 1 included.
Clear filters94 of 94 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
Abbott 1
SibutraminePhase 3
No dated milestone in 2025 to 2030
AbbVie 2
ABBV-295Phase 2
No dated milestone in 2025 to 2030
GUB014295Phase 1
No dated milestone in 2025 to 2030
Aconcagua Bio, Inc 1
ACCG-2671Phase 1/2
No dated milestone in 2025 to 2030
Alizyme 1
CetilistatPhase 1
No dated milestone in 2025 to 2030
Altimmune 1
PemvidutidePhase 2
No dated milestone in 2025 to 2030
Amgen 1
Maridebart CafraglutidePhase 3
Registry, Jan 21, 2027
Arrowhead 1
ARO-ALK7Phase 1/2
Registry, Feb 2027
Ascletis Pharma (China) Co 1
ASC30Phase 3
No dated milestone in 2025 to 2030
AstraZeneca 5
CotadutidePhase 1
No dated milestone in 2025 to 2030
ElecoglipronPhase 3
Registry, Nov 18, 2026
ExenatidePhase 3
No dated milestone in 2025 to 2030
PramlintidePhase 2/3
No dated milestone in 2025 to 2030
AZD6234Phase 3
Registry, May 4, 2027
Biohaven Therapeutics 1
TaldefgrobepPhase 2
No dated milestone in 2025 to 2030
Boehringer Ingelheim 1
SurvodutidePhase 3
Registry, Dec 8, 2026
BrightGene Bio-Medical Technology Co 1
BGM0504Phase 3
Registry, Feb 28, 2027
Carmot Australia First Pty Ltd 1
CT-996Phase 1
No dated milestone in 2025 to 2030
Carmot Therapeutics, Inc 1
CT-868Phase 2
No dated milestone in 2025 to 2030
Company n/r 3
BeinaglutideStage n/r
No dated milestone in 2025 to 2030
DulaglutidePhase 3
No dated milestone in 2025 to 2030
LoxenatidePhase 2/3
No dated milestone in 2025 to 2030
Corbus Pharmaceuticals 1
CRB-913Phase 1
No dated milestone in 2025 to 2030
CSPC Baike (Shandong) Biopharmaceutical Co 1
TG103Phase 3
No dated milestone in 2025 to 2030
Eli Lilly 8
TirzepatideApproved
Registry, Jan 2027
OrforglipronApproved
Registry, Sep 6, 2027
RetatrutidePhase 3
Registry, Mar 14, 2027
EloralintidePhase 3
Registry, Mar 2028
Eloralintide And TirzepatidePhase 3
No dated milestone in 2025 to 2030
LY4086940Phase 2
No dated milestone in 2025 to 2030
BrenipatidePhase 1
No dated milestone in 2025 to 2030
BimagrumabPhase 2
Registry, Dec 31, 2028
Empros Pharma AB 1
OrlistatApproved
No dated milestone in 2025 to 2030
Fujian Shengdi Pharmaceutical Co 1
RibupatidePhase 3
Registry, Oct 31, 2027
Gan & Lee Pharmaceuticals 1
BofanglutidePhase 3
Registry, Jun 30, 2027
Gasherbrum Bio, Inc 1
AleniglipronPhase 3
No dated milestone in 2025 to 2030
GSK 1
AlbiglutidePhase 3
No dated milestone in 2025 to 2030
Guangdong Raynovent Biotech Co 1
RAY1225Phase 3
No dated milestone in 2025 to 2030
Hangzhou Sciwind Biosciences Co 1
EcnoglutidePhase 3
Registry, Jan 5, 2027
Hanmi 1
HM15211Phase 1
No dated milestone in 2025 to 2030
Hengrui 1
NoiiglutidePhase 3
No dated milestone in 2025 to 2030
Huadong Medicine 3
HDM1002Phase 3
No dated milestone in 2025 to 2030
HDM1702Phase 3
No dated milestone in 2025 to 2030
HDM1005Phase 3
Registry, Dec 2026
Innovent 1
MazdutidePhase 3
Registry, Dec 31, 2026
Inversago Pharma 1
MonlunabantPhase 2
No dated milestone in 2025 to 2030
Merck 1
EfinopegdutidePhase 1
No dated milestone in 2025 to 2030
MindRank AI Ltd 1
MDR-001Phase 3
No dated milestone in 2025 to 2030
NeuroBo Pharmaceuticals Inc 1
DA-1726Phase 1
Registry, Nov 9, 2026
NeuroSearch 1
TesofensinePhase 2
No dated milestone in 2025 to 2030
Novo Nordisk 9
SemaglutideApproved
Registry, Sep 6, 2028
Registry, Mar 2027
ZenagamtidePhase 3
Registry, Jun 12, 2028
LiraglutideApproved
No dated milestone in 2025 to 2030
Oral SemaglutidePhase 3
Registry, Feb 22, 2028
CagrilintidePhase 3
Registry, Jan 26, 2027
NNC0519-0130Phase 2
No dated milestone in 2025 to 2030
NNC0165-1875Phase 2
No dated milestone in 2025 to 2030
LorcaserinPhase 1/2
No dated milestone in 2025 to 2030
Orexigen Therapeutics, Inc 1
Naltrexone And BupropionPhase 3
Registry, Dec 31, 2030
PegBio Co 1
VisepegenatidePhase 1/2
No dated milestone in 2025 to 2030
Pfizer 5
BerobenatidePhase 3
Registry, Sep 21, 2027
DanuglipronPhase 1
No dated milestone in 2025 to 2030
MET-233IPhase 1/2
No dated milestone in 2025 to 2030
PF-07976016Phase 2
No dated milestone in 2025 to 2030
LotiglipronPhase 2
No dated milestone in 2025 to 2030
Regeneron 3
HS-20094Phase 3
Registry, Nov 13, 2026
GaretosmabPhase 2
No dated milestone in 2025 to 2030
TrevogrumabPhase 2
No dated milestone in 2025 to 2030
Rhythm 2
SetmelanotidePhase 3
Registry, Mar 13, 2027
LB54640Phase 2
No dated milestone in 2025 to 2030
Roche 3
PetrelintidePhase 3
Registry, Oct 20, 2028
TaspoglutidePhase 3
No dated milestone in 2025 to 2030
CT-388Phase 3
Registry, Nov 12, 2027
Sanofi 3
LixisenatidePhase 3
No dated milestone in 2025 to 2030
RimonabantPhase 3
No dated milestone in 2025 to 2030
EfpeglenatidePhase 3
No dated milestone in 2025 to 2030
Scholar Rock 1
ApitegromabPhase 2
No dated milestone in 2025 to 2030
Scohia 1
SCO-940/CT-G32Preclinical
No dated milestone in 2025 to 2030
Shandong Suncadia Medicine Co 1
SafiglipronPhase 3
No dated milestone in 2025 to 2030
Shanghai Yinnuo Pharmaceutical Technology Co 1
Efsubaglutide AlfaPhase 2/3
Registry, Nov 30, 2026
Shanghai Yinnuo Pharmaceutical Technology Co. 1
SupaglutidePhase 2/3
No dated milestone in 2025 to 2030
Shionogi 1
VelneperitPhase 2
No dated milestone in 2025 to 2030
Skye Bioscience 1
NimacimabPhase 2
Registry, Nov 20, 2026
Terns, Inc 1
TERN-601Phase 2
No dated milestone in 2025 to 2030
The United Bio-Technology (Hengqin) Co 1
UBT251Phase 3
Registry, Jan 14, 2027
Verdiva Bio Dev Limited 1
VRB-101Phase 2
No dated milestone in 2025 to 2030
Veru Inc 1
EnobosarmPhase 2
No dated milestone in 2025 to 2030
Viking Therapeutics 2
VK2735Phase 3
Registry, Jul 2027
Oral VK2735Phase 3
No dated milestone in 2025 to 2030
Vincentage Pharma Co 1
VCT220Phase 3
No dated milestone in 2025 to 2030
VIVUS 1
Phentermine And TopiramatePhase 3
No dated milestone in 2025 to 2030
Zafgen 1
BeloranibPhase 3
No dated milestone in 2025 to 2030
Zealand Pharma 1
DapiglutidePhase 2
No dated milestone in 2025 to 2030